Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003YN2
HKD
5.15
-0.4 (-7.21%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Dawnrays Pharmaceutical Holdings Ltd.
TOT BIOPHARM International Co. Ltd.
Shanghai Henlius Biotech, Inc.
Charmacy Pharmaceutical Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Clover Biopharmaceuticals Ltd.
Hua Medicine Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Fusen Pharmaceutical Co., Ltd.
Why is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ?
1
High Debt company with Weak Long Term Fundamental Strength
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 23
  • NO KEY NEGATIVE TRIGGERS
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
22.33%
1.26
42.95%
Hang Seng Hong Kong
27.36%
1.06
25.88%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
1.37%
EBIT Growth (5y)
-14.75%
EBIT to Interest (avg)
2.33
Debt to EBITDA (avg)
47.62
Net Debt to Equity (avg)
0.04
Sales to Capital Employed (avg)
0.34
Tax Ratio
12.05%
Dividend Payout Ratio
56.84%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.05%
ROE (avg)
2.01%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
0.10
EV to EBIT
4.50
EV to EBITDA
2.69
EV to Capital Employed
0.13
EV to Sales
0.32
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
2.99%
ROE (Latest)
4.46%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend